Brokers usually take bids until: Zerodha 4:45 PM, Groww 4:50 PM, Angel One and Upstox 5:00 PM (HNI 4:00 PM). Check the exact time with your broker or bank.
Total Issue Size
Fresh Issue + Offer For Sale
Fresh Issue (FI)
Proceeds go to the company
Offer For Sale (OFS)
Proceeds go to the existing investors
Repayment or prepayment of borrowings
A portion of the net proceeds from the fresh issue is earmarked to repay or prepay outstanding debt, reducing the company's borrowing costs.
Funding incremental working capital requirements
Proceeds are also intended to support the company's growing working capital needs as operations scale.
Funding inorganic growth through acquisitions
A portion of the proceeds is reserved for pursuing strategic acquisitions as part of the company's growth strategy.
General corporate purposes
The remaining net proceeds are to be used for general corporate purposes.
(₹ in Crore)
Tap a bar to highlight a metric across periods and show its values.
No peer comparisons added yet.
Akums Drugs & Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) based in India, incorporated in 2004. The company develops, manufactures and supplies a wide range of dosage forms, including tablets, capsules, liquid orals, injectables and other formulations, for domestic and overseas pharmaceutical clients. It also has a presence in formulation marketing and active pharmaceutical ingredient (API) manufacturing, spanning multiple layers of the pharmaceutical value chain. The company operates a network of manufacturing units with substantial annual production capacity and employs a large workforce spread across full time and contract staff. It counts a majority of India's largest pharmaceutical companies among its client base, reflecting long standing relationships built over almost two decades of operations. Its equity shares were listed on the NSE and BSE in August 2024 following a book built initial public offering. Akums positions itself as one of the largest CDMO players in the Indian domestic market by revenue, production capacity and number of clients, with a market share that grew over the years leading up to its listing. Its integrated presence across contract manufacturing, formulation marketing and API production is intended to diversify revenue streams and provide multiple avenues for growth within the pharmaceutical outsourcing industry.
No anchor investors added yet.
Source: RHP • Analysis provided for informational purposes
Last Updated: 14 July 2026, 5:30 AM
Largest domestic CDMO by scale
The company is among the largest pharmaceutical contract development and manufacturing organizations in India by revenue, production capacity and number of clients, having steadily grown its share of the domestic CDMO market.
Broad, long standing client relationships
It serves a diverse set of clients including most of India's largest pharmaceutical companies, supported by growing in house research and development capabilities across its product range.
Integrated pharmaceutical value chain presence
Operations span contract manufacturing, formulation marketing and API production, which diversifies revenue sources and provides several avenues for growth while reducing reliance on any single business line.
Ongoing legal proceedings
The company, certain promoters, subsidiaries and directors are party to various legal proceedings, and unfavourable outcomes could adversely affect the business and its reputation.
Regulatory inspection exposure
Manufacturing facilities are subject to periodic inspections and audits by regulators and clients, and adverse findings could lead to regulatory action or reputational harm.
Client concentration risk
A significant portion of revenue is derived from a relatively small group of clients, so the loss of, or reduced business from, any of them could materially affect results.
Akums Drugs & Pharmaceuticals Limited
Plot No. 131 to 133, Block-C, Mangolpuri Industrial Area, Phase-I, Delhi 110083
View on Maps →MUFG Intime India Private Limited
No financial information whatsoever published anywhere, within this website, should be considered as an advice to buy or sell securities or invest in IPOs, or as a guide to doing so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions.
We are not a SEBI Registered analyst. Readers must consult a qualified financial advisor prior to making any actual investment decisions, based on information published on this website. The information on this website is based on information available as on date coupled with market perceptions.
You agree with the terms and conditions to use this website.
Grey-market disclaimer. GMP shown here is grey-market news only. We do not trade or deal in the grey market or subject-to rates, nor do we recommend trading in the grey market.
Not investment advice. IPO Nex is an information tool, not investment advice. We do not recommend buying or selling any securities. Always do your own research before applying to any IPO.
IPO Nex does not guarantee any listing gain or return. IPO investments are subject to market risks.
All times are IST.
© 2026 IPO Nex by Niota. All rights reserved.